Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Cepheid's Enterprise Value is $3,862.1 Mil.
Cepheid's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 was $-19.7 Mil. Therefore, Cepheid's EV-to-EBIT ratio for today is -196.14.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Cepheid's Enterprise Value is $3,862.1 Mil.
Cepheid's EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 was $17.2 Mil. Therefore, Cepheid's EV-to-EBITDA ratio for today is 224.17.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Cepheid's Enterprise Value is $3,862.1 Mil.
Cepheid's Revenue for the trailing twelve months (TTM) ended in Sep. 2016 was $596.3 Mil. Therefore, Cepheid's EV-to-Revenue ratio for today is 6.48.
Cepheid Enterprise Value Historical Data
The historical data trend for Cepheid's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Cepheid's Enterprise Value
For the Diagnostics & Research subindustry, Cepheid's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cepheid's Enterprise Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cepheid's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Cepheid's Enterprise Value falls into.
Cepheid Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Cepheid's Enterprise Value for the fiscal year that ended in Dec. 2015 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cepheid (NAS:CPHD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Cepheid's current Enterprise Value is $3,862.1 Mil.
Cepheid's EBIT for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-19.7 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Cepheid's current Enterprise Value is $3,862.1 Mil.
Cepheid's EBITDA for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $17.2 Mil.
Cepheid's current Enterprise Value is $3,862.1 Mil.
Cepheid's Revenue for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $596.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cepheid Enterprise Value Related Terms
Thank you for viewing the detailed overview of Cepheid's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Cepheid was incorporated in the State of California on March 4, 1996. The Company is a molecular diagnostics company that develops, manufactures and markets integrated systems for testing in the clinical market, as well as for application in its non-clinical markets. The Company's systems enable molecular testing for organisms and genetic-based diseases by automating otherwise complex manual laboratory procedures. The Company's product portfolio consists of tests, reagents and systems for the clinical and non-clinical markets. The Company's two systems are the GeneXpert and SmartCycler. The GeneXpert system, offers services in the clinical market, integrates sample preparation in addition to DNA amplification and detection. The GeneXpert system is designed for user types ranging from reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals and doctors' offices. The SmartCycler system integrates DNA amplification and detection to allow rapid analysis of a sample. Company faces competition from a number of companies that offer products to its target markets. Company has patents covering technologies of its own and has licensed technologies from others. In addition to patents, it rely on a combination of trade secrets, copyright and trademark laws, nondisclosure agreements, licenses and other contractual provisions and technical measures to maintain and develop its competitive position with respect to intellectual property. In the Clinical market, its products are regulated as medical device products by the FDA and comparable agencies in other countries. For the Non-Clinical market, all of its products are being produced under ISO 13485 and Quality System Regulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CPHD has been successfully added to your 